John Fanikos Praises Nathan Connell’s Efforts on Hemophilia Gene Therapy in Boston
John Fanikos, Director of Strategic Initiatives at North American Thrombosis Forum, shared a post on LinkedIn:
“Hemophilia historically has been seen as a ‘royal disease’ because of its occurrence in the royal families of Spain, Germany and Russia.
Today it is known as a genetic disorder where bleeding occurs because of low levels of blood clotting Factor 8 (VIII) or Factor 9 (IX). As simple as a missing gene on a chromosome that provides the blueprint for the protein Factor.
Enter gene therapy.
Kudos to Dr Nathan Connell, who worked feverishly to bring this treatment to the Boston area.
You can hear the treatment results of his first patient on the CBS news and follow his expertise at the Vasculearn Network”
Nathan Connell’s first patient results featured on CBS News.
Follow his expertise on the Vasculearn Network.
Stay informed with Hemostasis Today.
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology